Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irofulven + capecitabine
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Irofulven + capecitabine is a combination of two small molecule chemotherapeutic agents used in clinical trials for the treatment of advanced solid tumors and certain cancers such as thyroid cancer. Irofulven is a semisynthetic derivative of illudin S that acts as an alkylating agent causing DNA damage and apoptosis in tumor cells. Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within tumor tissue; 5-FU inhibits thymidylate synthase and interferes with DNA synthesis, leading to cell death. The combination has been studied for synergistic antitumor activity[2][4][5][6].
- Other names
- 6-hydroxymethylacylfulveneMGI-114MGI114MGI 114HMAF5'-deoxy-5-fluorocytidineN4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on Irofulven + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Irofulven + capecitabine.